Post-earnings recap
Reported
Mon, Mar 9, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Crinetics Pharmaceuticals reported a loss of $0.60 per share, with no revenue figures disclosed. The stock fell by 3.22% following the earnings report, likely reflecting investor concerns over the lack of guidance and clarity on future performance. The absence of revenue data may have added to uncertainty among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.60 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious approach due to the current market conditions. They emphasized their commitment to ongoing clinical development.
Management did not provide specific guidance for the upcoming quarters.
The company is focused on advancing its clinical programs.